Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Autolus Therapeutics plc changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of AUTL: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders7366−7
Shares52.5M53.0M+545.3K (+1.0%)
Value$272.3M$228.6M−$43.6M (−16.0%)

New holders (8)

Institutions that held Autolus Therapeutics plc at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to AUTL in Q1 2022
InstitutionSharesValue% of portfolio
Frazier Life Sciences Management, L.P.3,746,857$15.6M1.33%
LGT Capital Partners Ltd.500,000$2.08M0.06%
DAFNA Capital Management LLC496,150$2.07M0.54%
Deep Track Capital, LP382,559$1.59M0.10%
Privium Fund Management B.V.33,000$138.0K0.03%
Moloney Securities Asset Management, LLC20,000$83.0K0.02%
Barclays PLC15,074$63.0K0.00%
Captrust Financial Advisors500$2.00K0.00%

Sold out (15)

Institutions that held Autolus Therapeutics plc at the end of Q4 2021 and filed for Q1 2022 without it.